

## CURE ID Long COVID Treatment Survey

TLC:  
Treatments for  
Long COVID  
Survey

Are you a Long COVID patient interested in participating in a survey to help inform research, identify promising treatments, or treatments that are ineffective or harmful? NCATS, FDA, and C-path join forces with patients and clinicians for the CURE ID TLC program.

<https://cure.ncats.io>



Join the NIH, FDA, and partners in advancing our understanding of the treatments of Long COVID. What treatments are you taking and how have they impacted you? Take the CURE ID Treatments for Long COVID Survey now by visiting [CURE-ID \(ncats.io\)](https://cure.ncats.io) or download the "CURE ID" mobile app now!


## The Sick Times highlights CURE ID for Long COVID

## Long COVID surveys from a FDA/NIH initiative ask which drug help alleviate symptoms

Last month, a U.S. government initiative launched a pair of surveys to collect information about how people with Long Covid are managing their symptoms. Data from these surveys, one for people with Long Covid and one for their doctors, will inform priorities for clinical trials. Called [CURE ID](https://cure.ncats.io), this federal initiative is a collaboration between the Food & Drug Administration (FDA) and the National Center for Advancing Translational Sciences, under the National Institutes of Health (NIH), along with other research partners. The agencies started CURE ID in 2019, aiming to identify how existing drugs might be repurposed for emerging and complex diseases.

Read more here: [Long Covid surveys from a FDA/NIH initiative ask which drugs help alleviate symptoms - The Sick Times](https://www.fda.gov/news-events/press-announcements/long-covid-surveys-fda-nih-initiative-ask-which-drugs-help-alleviate-symptoms-the-sick-times)

## Unlocking the Power of Data for Faster Health Solutions



February 7, 2024: Unlocking the Power of Data for Faster Health Solutions. This Director's Message is part of a series on how [National Center for Advancing Translational Sciences \(NCATS\)](https://www.ncats.nih.gov/) tackles persistent problems in translation.

Finding important links among different types of data is key to bringing more treatments to all people more quickly. NCATS has invested in new ways to connect, access, and learn from large and complex data sets. They also have created and used data tools and methods in new ways to speed translational research.

In this message, Joni L. Rutter, Ph.D., Director, National Center for Advancing Translational Sciences, speaks on the importance of making data useful to all researchers. This includes CURE ID's work and emphasis on the experiences of patients and providers with long COVID.

Read the whole message here: <https://linkd.in/eAlhaiYE>

For more information on CURE ID: <https://linkd.in/ePCTgZV>

For more information on CDRC: <https://linkd.in/emnWBmG2>

## Events

## Public meeting: FDA Rare Disease Day 2024

March 1st, 2024, Virtual from 9:00 AM - 4:30 PM ET

FDA will host Rare Disease Day, a virtual public meeting, on March 1, 2024 in global observance of Rare Disease Week.

This year's Rare Disease Day is dedicated to patients and health care professionals. Panels will discuss:

- The legal framework for approving studies and medical products at FDA
- What FDA does during review processes to approve medical products
- Decentralized clinical trials and digital health technologies
- Where to find important information and documents related to clinical trials
- Information that can be obtained from medical product labels
- Legal and ethical requirements for consent forms in clinical trials
- FDA initiatives to advance medical product development for rare diseases
- Ways for patients to engage with FDA

Register Here: <https://www.surveymonkey.com/r/FDARD2024>

## IDR24: International Drug Repurposing Conference

March 6 & 7 2024, Barcelona, Spain

Bridging Boundaries: innovating, connecting, and reshaping drug repurposing, which is the REMEDI4ALL Annual Conference in Barcelona, Spain, March 6-7th, 2024 with pre-meeting of MERIT - the group of international regulators and publicly funded repurposing initiatives on March 5th. Heather Stone will be co-leading the opening plenary on medicines repurposing for all and Keyla Tumas, Shira Strongin, Marco Schito, and Smith Heavener will also be attending. We look forward to meeting you there!

For more information: <https://remedi4all.org/international-drug-repurposing-conference/>

## AMIA 2024 Informatics Summit

March 18th - 21st, Boston, MA

Join us at the AMIA 2024 Informatics Summit and experience content dedicated to translational bioinformatics, precision medicine, clinical research informatics, data science and artificial intelligence (AI) in one integrated conference. CDRC members will be presenting at this conference.


For more information: [AMIA 2024 Informatics Summit | AMIA - American Medical Informatics Association](https://www.amia.org/2024/summit)

## Trending Articles

[Free-living amoebae promote Candida auris survival and proliferation in water - PubMed \(nih.gov\)](https://pubmed.ncbi.nlm.nih.gov/37444444/)

[Safety and efficacy of dolutegravir as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials - The Lancet HIV](https://www.thelancet.com/journal/S0140-6736(24)00000-0)

## Awareness Month



## CURE ID/CDRC Clinical Scholar's Program

## Looking to become a social media ambassador?

CURE ID is looking to recruit individuals interested in help promoting our web-based app. The platform enables healthcare providers, patients, and care partners to share their real-world experiences of treatment using repurposed drugs. We currently have are recruiting for the next group of scholars.

This is an unpaid position but can win CURE ID/CDRC swag.

If interested please reach out to [cbassetti@c-path.org](mailto:cbassetti@c-path.org)



## Be Heard

## Tell Your Drug Repurposing Story in 2023

Our Impact stories share the value and impact C-Paths and CDRCs work brings to patients, patient organizations, drug developers, the academic community, regulators and more. Enjoy and share! [Impact Stories | Critical Path Institute \(c-path.org\)](https://www.c-path.org/impact-stories)

Reach out to the Communication and Patient Engagement Manager, Claire Bassetti at [cbassetti@c-path.org](mailto:cbassetti@c-path.org) if interested in sharing your story through an Impact Story.


## Joining the CDRC



The CURE Drug Repurposing Collaboratory (CDRC) is a public-private partnership initiated in June 2020 by C-Path and the U.S. Food and Drug Administration (FDA) in partnership with the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH).

If interested, please feel free to get involved with the CURE Drug Repurposing Collaboratory (CDRC), here: <https://c-path.org/cdrc>

## Collaborators



## Brought to you by



## Visit CURE ID

Visit the CURE ID website for more information.  
<https://cure.ncats.io>



## Get the CURE ID Mobile App



You received this email because you registered for CURE ID or signed up to receive our monthly newsletter. If you have any questions regarding this communication, please contact us at [curesupport@nih.gov](mailto:curesupport@nih.gov)